A clinical study to assess the effectiveness and safety of LOXO-305 compared to standard of care treatment chosen by the Investigator in patients with previously treated Mantle Cell Lymphoma

Phase 1

• Conditions: Mantle cell lymphoma; MedDRA version: 20.0Level: LLTClassification code 10026799Term: Mantle cell lymphoma NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps); Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2020-004553-72-DE
• Lead Sponsor: oxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-03-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• At least 18 years of age
• Confirmed diagnosis by local laboratory of MCL with documentation of
overexpression of cyclin D1 with at least one B-cell marker (e.g., CD19,
CD20, or PAX5) and/or t (11;14) by cytogenetics, fluorescent in situ
hybridization (FISH) or polymerase chain reaction.
• Previously treated with at least one prior line of systemic therapy for
MCL.
• Measurable disease by PET-CT and/or CT/MRI as defined by Lugano
criteria and aligned with protocol imaging requirements:
- at least one nodal lesion (> 1.5 cm in long axis) or extranodal
lesion (> 1.0 cm in long axis) measurable in 2 dimensions, not
previously radiated (unless progression has been radiographically
documented following radiation therapy).
• Documented evidence of radiographically and/or histologically
confirmed PD on the most recent line of therapy or relapse prior to study
enrollment.
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Adequate organ function
• Must have life expectancy of at least 3 months
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 200
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 300

Exclusion Criteria

• Current suspected or confirmed active central nervous system (CNS)
involvement with MCL or previous CNS involvement.
• Prior treatment with an approved or investigational BTK inhibitor.
• Major surgery within 4 weeks prior to randomization.
• History of bleeding diathesis.
• History of stroke or intracranial hemorrhage within 6 months of
randomization.
• History of allogeneic or autologous stem cell transplant (SCT) or
chimeric antigen receptor-modified T-cell (CAR-T) therapy within 60
days of randomization.
• Significant cardiovascular disease.
• Prolongation of the QT interval corrected for heart rate (QTcF) > 470
msec during Screening.
• Known human immunodeficiency virus (HIV) infection, regardless of
CD4 count.
• Known active hepatitis B virus (HBV) or hepatitis C virus (HCV)
infection.
• Known active cytomegalovirus (CMV) infection. Unknown or negative
status are eligible.
• Pregnancy during the study or within 3
months of the last dose of study treatment.
• Clinically significant active malabsorption syndrome or other condition
likely to affect GI absorption of the study drug.
• Evidence of other clinically significant uncontrolled condition(s)
including but not limited to, uncontrolled systemic bacterial, viral, fungal
or parasitic infection (except for fungal nail infection), or other clinically
significant active disease process which in the opinion of the
Investigator and medical monitor may pose a risk for patient
participation. Screening for chronic conditions is not required.
• History of second malignancy unless in remission for at least 2 years;
in-situ carcinomas not requiring treatment intervention, non-melanoma skin cancer curatively treated, nonmetastatic
breast, or nonmetastatic prostate cancer where hormonal therapy is
being continued as standard of care are allowed.
Prior/Concomitant Therapy
• Ongoing chronic treatment with strong cytochrome P450 3A4
(CYP3A4) inhibitors or inducers which cannot be stopped within 3-5
half-lives of the CYP3A inhibitor therapy prior to start of study drug
treatment.
Because of their effect on CYP3A4, use of any of the following within 3
days of study therapy start is prohibited: Grapefruit or grapefruit
products, Seville oranges or products from Seville oranges, Star fruit or
star fruit products.
• Steroid use with antineoplastic intent within 7 days of study drug
initiation.
• Patients requiring therapeutic anticoagulation with warfarin or another
vitamin K antagonist.
• Vaccination with a live vaccine within 28 days prior to randomization.
• Have a known hypersensitivity to any of the excipients of pirtobrutinib
or to the intended covalent BTK inhibitor if randomized to control arm.
• Laction, or plan to breastfeed during the study or within 2 weeks of the
last dose of study treatment

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: To compare PFS of pirtobrutinib as monotherapy (Arm A) to Investigator choice of covalent BTK inhibitor monotherapy (Arm<br>B) in patients with previously treated MCL;Secondary Objective: -To compare efficacy of pirtobrutinib as monotherapy (Arm A) to Investigator choice of covalent BTK inhibitor monotherapy (Arm B) treatment arms<br>-To evaluate the safety and tolerability of each treatment arm<br>-To evaluate the patient-reported outcomes;Primary end point(s): Assessed by independent review committee (IRC)<br>• PFS per Lugano criteria;Timepoint(s) of evaluation of this end point: The time from the date of randomization until PD or death from any cause, whichever occurs first.